Synthetic analog · 9 amino acids · 1,048.3 Da

Selepressin studies and research data

PepBank has 11 selepressin studies with results. All of them gave selepressin, with 63 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.

Searches 63 results and 34 papers. Newer studies from Europe PMC

Results in people

16% of 63 results

Results in animals

67% of 63 results

Results in lab cells

17% of 63 results

From computer models

0% of 63 results

The molecule

Selepressin identity

Identifiers, parent molecule, targets and development stage, from curated data.

Selepressin (FE 202158) is a synthetic vasopressin analogue and a selective V1A receptor agonist. SEPSIS-ACT found no significant improvement in ventilator- and vasopressor-free days versus placebo. The trial stopped for futility after its first part.

Kind: Synthetic analog · 9 residues
Identifiers: ChEMBLCHEMBL1817709 (opens in a new tab)PubChem CID53330936 (opens in a new tab)UNII8P2T76M0SJ (opens in a new tab)DrugBankDB12495 (opens in a new tab)CAS876296-47-8IUPHAR11454 (opens in a new tab)
Parent: Analog of Arginine vasopressin (human) · residues 20-28The primary pharmacology paper defines [Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin. UniProt maps mature human vasopressin to residues 20-28. Substitution numbers refer to the mature nine-residue chain.
Development: Phase 3Ferring PharmaceuticalsFerring sponsored two phase 2 trials and the adaptive phase 2b/3 SEPSIS-ACT trial. SEPSIS-ACT stopped for futility after part 1, before its confirmatory part. The phase_3 field reflects the registered phase 2b/3 design, not completed confirmatory phase 3 testing. Current sponsor-wide development status remains unverified. Source (opens in a new tab)

Targets

Molecular targets with action and evidence source
Target	Action	Evidence
AVPR1AAVPR1AP37288 (opens in a new tab)	Full agonist	Primary functional reporter and binding assays establish selective human V1A receptor agonism.Source (opens in a new tab)

Sequence and structure

Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.

Sequence

9 amino acids · 4 modifications · 1 disulfide bond

H-

CFINCPG

Parent: Arginine vasopressin (human)

No sequence is listed for the parent, so no alignment is shown.The primary pharmacology paper defines [Phe2,Ile3,Hgn4,Orn(iPr)8]vasopressin. UniProt maps mature human vasopressin to residues 20-28. Substitution numbers refer to the mature nine-residue chain.

Properties

From identity sources

Formula: C₄₆H₇₃N₁₃O₁₁S₂
Molecular weight: 1,048.3 g/mol
Monoisotopic mass: 1,047.4994 Da

PubChem CID 53330936(opens in a new tab)retrieved 2026-10-27
GSRS UNII 8P2T76M0SJ(opens in a new tab)retrieved 2026-10-27
pubmed 21411496(opens in a new tab)retrieved 2026-10-27
iuphar gtopdb 11454(opens in a new tab)retrieved 2026-10-27

Calculated from the sequence

pKa set

Some values cannot be calculated. The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Average mass: Not calculated
Monoisotopic mass: Not calculated
Isoelectric point (pI): Not calculated
Net charge at pH 7.4: Not calculated
GRAVY (hydropathy): Not calculated
Extinction coefficient, 280 nm (Cys reduced): 0 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr · Pace et al. 1995 (ExPASy ProtParam); No Trp or Tyr: absorbance at 280 nm cannot measure this peptide.
Extinction coefficient, 280 nm (all Cys as cystines): 125 M⁻¹ cm⁻¹; 5500 x Trp + 1490 x Tyr + 125 x cystine · Pace et al. 1995 (ExPASy ProtParam)
Instability index: Not calculated
Aliphatic index: Not calculated
Boman index: Not calculated
Hydrophobic moment (μH): Not calculated

2 non-canonical residues (X) are not included in calculated values.
Defined and validated for proteins; use with care for short peptides.
Assumes an ideal alpha helix. Many short peptides are not helical.

@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses

Net charge by pH

No charge curve

The sequence has a non-canonical residue (X). Residue tables cover only the 20 standard amino acids.

Composition

Hydrophobic11% (1)I
Aromatic11% (1)F
Polar11% (1)N
Special44% (4)C G P
Non-canonical22% (2)X

9 residues. Each residue counts in one class; F and W count as aromatic.

A Ala0 · 0%

I Ile1 · 11%

L Leu0 · 0%

M Met0 · 0%

V Val0 · 0%

F Phe1 · 11%

W Trp0 · 0%

Y Tyr0 · 0%

H His0 · 0%

K Lys0 · 0%

R Arg0 · 0%

D Asp0 · 0%

E Glu0 · 0%

N Asn1 · 11%

Q Gln0 · 0%

S Ser0 · 0%

T Thr0 · 0%

C Cys2 · 22%

G Gly1 · 11%

P Pro1 · 11%

X Xaa2 · 22%

3D structure

PredictedAlphaFold DB · P01185

Loads the 3D viewer (3Dmol.js, about 150 KB) and the model file from AlphaFold DB (EMBL-EBI).

2D structure

Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).

SMILES fromPubChem CID 53330936(opens in a new tab)

CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCNC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCCC(=O)N

Results by area

Selepressin results by year and outcome

Counts are exact and come from studies that gave the peptide.

Studies by year

11 of 34 studies have results (32%), published 2011 to 2022. Top row: every study. Bottom row: studies with results about Selepressin, by class. The rows use different scales.

Studies
Human
Animal
Lab
Computer model
Natural levels, tool or combination only

Studies34 in all, 2010 to 2026

Studies with results11 in all, 2011 to 2022

Retracted studies are left out. A study with results in two classes counts in both.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

What the studies measured

People first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.

Selepressin studies on heart and blood vessels

37 results · people 5 · animals 26 · lab 6

Top 5 of 37 results

In septic shock, selepressin 2.5 ng/kg/minute maintained target blood pressure without norepinephrine in more patients than placebo.Critical care, 2017
In sheep with septic shock, early selepressin maintained cardiac pumping better than arginine vasopressin.Critical care medicine, 2016
In sheep with septic shock, early selepressin slowed the blood lactate increase compared with arginine vasopressin.Critical care medicine, 2016
In endotoxemic rabbits, selepressin reduced intestinal blood flow significantly less than arginine vasopressin.Peptides, 2020
In cells, selepressin reduced thrombin-induced leakage across human lung blood vessel cell layers in a concentration-dependent manner.The Journal of pharmacology and experimental therapeutics, 2020

Selepressin studies on side effects

5 results · people 3 · animals 2 · lab 0

5 results

In septic shock, adverse event frequency was similar with selepressin 2.5 ng/kg/minute and placebo.Critical care, 2017
In worldwide safety reports, selepressin was not significantly linked to intestinal blood supply loss in the reporting analysis.Frontiers in medicine, 2022
In sheep, FE 202158 did not significantly change the clotting marker ratio compared with sham.Critical care medicine, 2012
In septic shock, one of two patients receiving selepressin 3.75 ng/kg/minute stopped infusion for possible safety reasons.Critical care, 2017
In sheep, FE 202158 produced a lower clotting marker ratio than arginine vasopressin.Critical care medicine, 2012

Selepressin studies on lungs and breathing

5 results · people 1 · animals 4 · lab 0

Top 4 of 5 results

In septic shock, selepressin 2.5 ng/kg/minute increased the proportion of days alive without ventilation compared with placebo.Critical care, 2017
In sheep with septic shock, early selepressin produced less lung fluid accumulation than arginine vasopressin.Critical care medicine, 2016
In sheep with septic shock, early selepressin produced less lung fluid accumulation than norepinephrine.Critical care medicine, 2016
In sheep with septic shock, late selepressin produced lower lung wet/dry weight ratios than arginine vasopressin.Critical care medicine, 2016

Selepressin studies on salt, water and minerals

3 results · people 1 · animals 2 · lab 0

3 results

In septic shock, fluid accumulation was lower from day 5 onward with selepressin 2.5 ng/kg/minute than placebo.Critical care, 2017
In sheep with septic shock, early selepressin produced less fluid accumulation than arginine vasopressin.Critical care medicine, 2016
In sheep with septic shock, early selepressin produced less fluid accumulation than norepinephrine.Critical care medicine, 2016

Selepressin studies on immune system and inflammation

4 results · people 0 · animals 4 · lab 0

Top 3 of 4 results

In sheep with septic shock, early selepressin produced lower interleukin-6 levels than arginine vasopressin.Critical care medicine, 2016
In sheep with septic shock, early selepressin produced lower interleukin-6 levels than norepinephrine.Critical care medicine, 2016
In sheep with septic shock, early selepressin produced lower nitrite/nitrate levels than arginine vasopressin.Critical care medicine, 2016

Selepressin studies on receptors and cell signals

7 results · people 0 · animals 2 · lab 5

Top 5 of 7 results

In dogs, selepressin and arginine vasopressin narrowed peripheral vessels more than they increased coronary resistance.Shock, 2013
In cells, selepressin strongly increased p53 expression in human lung blood vessel cells.The Journal of pharmacology and experimental therapeutics, 2020
In lab tests, FE 202158 was among the most potent and selective compounds reported.Journal of medicinal chemistry, 2011
In rats, FE 202158 had a short duration of blood pressure action similar to arginine vasopressin.Journal of medicinal chemistry, 2011
In cells, selepressin suppressed an inflammatory RhoA pathway in human lung blood vessel cells.The Journal of pharmacology and experimental therapeutics, 2020

Selepressin studies on kidneys and bladder

1 result · people 0 · animals 1 · lab 0

1 result

In rats, FE 202158 lacked the urine-reducing activity seen with AVP at the tested dose.The Journal of pharmacology and experimental therapeutics, 2011

Selepressin studies on survival and serious illness

1 result · people 0 · animals 1 · lab 0

1 result

In sheep with septic shock, selepressin-treated animals lived longer than the other study animals.Critical care medicine, 2016

Trials and papers

Selepressin trials

Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.

StatusPhase

3 trials match. Highest phase first. Data from ClinicalTrials.gov.

Trials on this page (3 of 3)

3 trials · 2 completed · 1 stopped early · 3 with posted results

Completed
Ongoing
Not yet recruiting
Stopped
Estimated dates (est.)
Results posted

20102012201420162018

Ph 2
Effects of the V1a Agonist FE 202158 in Patients With Septic Shock
NCT01000649
Nov 2009 to Sept 2011
Ph 2
Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
NCT01612676
Jun 2012 to Nov 2013
Ph 2/3
SEPSIS-ACT
NCT02508649
Jul 2015 to 26 Feb 2018
Terminated
Terminated

3 trials · 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 2/3Results postedNCT02508649

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Ferring Pharmaceuticalsn = 868Jul 2015 to 26 Feb 2018

Septic Shock

Trial page ClinicalTrials.govUpdated 6 Apr 2021

CompletedPhase 2Results postedNCT01000649

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

Ferring Pharmaceuticalsn = 53Nov 2009 to Sept 2011

Septic Shock

Trial page ClinicalTrials.govUpdated 25 Sept 2017

CompletedPhase 2Results postedNCT01612676

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

Ferring Pharmaceuticalsn = 31Jun 2012 to Nov 2013

Septic Shock

Trial page ClinicalTrials.govUpdated 23 Mar 2017

Papers

Studies on this peptide. Some have results. The others have none yet.

Sort

Design

34 studies match. Retracted studies are left out.

Showing 25 of 34 studiesquery qry_815062709f3c2be3e1bfbf60

Studies with results

11 studies in all, 8 on this page

Randomized controlled trial · 2017

9 results

Selepressin, a novel selective vasopressin V_1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.

Russell et al. 2017Critical care (London, England)n = 40cited by 77

PMID 28807037PMC5557574DOI 10.1186/s13054-017-1798-7PUB-28807037

CC BY9 results where Selepressin was given

Download PDF See results (9)

Animal study (in vivo) · sheep · 2016

19 results

A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock.

He et al. 2016Critical care medicinen = 46cited by 64

PMID 26496451PMC4684247DOI 10.1097/ccm.0000000000001380PUB-26496451

Rights unknown19 results where Selepressin was given

Source link See results (19)

Animal study (in vivo) · sheep · 2014

2 results

The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.

Maybauer et al. 2014Critical care medicinecited by 59

PMID 24674922PMC4346299DOI 10.1097/ccm.0000000000000300PUB-24674922

Rights unknown1 result where Selepressin was given (plus 1 on tools or combinations, listed separately)

Source link See results (2)

Animal study (in vivo) · rat · 2011

2 results

New, potent, selective, and short-acting peptidic V1a receptor agonists.

Wisniewski et al. 2011Journal of medicinal chemistrycited by 38

PMID 21688787DOI 10.1021/jm200278mPUB-21688787

Full text at the publisher2 results where Selepressin was given

Publisher page See results (2)

Animal study (in vivo) · rat · 2011

5 results

Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.

Laporte et al. 2011The Journal of pharmacology and experimental therapeuticscited by 31

PMID 21411496DOI 10.1124/jpet.111.178848PUB-21411496

Full text at the publisher5 results where Selepressin was given

Publisher page See results (5)

Observational study · 2022

1 result

Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review.

Jozwiak et al. 2022Frontiers in medicinecited by 23

PMID 35677822PMC9168038DOI 10.3389/fmed.2022.826446PUB-35677822

CC BY1 result where Selepressin was given

Download PDF See results (1)

Animal study (in vivo) · sheep · 2012

2 results

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor.

Rehberg et al. 2012Critical care medicinen = 6cited by 14

PMID 22488005PMC7461604DOI 10.1097/ccm.0b013e31824e0fe5PUB-22488005

Rights unknown2 results where Selepressin was given

Source link See results (2)

Animal study (in vivo) · dog · 2013

4 results

Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs.

Boucheix et al. 2013Shock (Augusta, Ga.)n = 8cited by 12

PMID 23429645DOI 10.1097/shk.0b013e31828aac4bPUB-23429645

Rights unknown4 results where Selepressin was given

Source link See results (4)

More studies

23 studies in all, 17 on this page

PubMed tag: review-article, Review · 2018

Vasoplegia treatments: the past, the present, and the future.

Levy et al. 2018Critical care (London, England)cited by 160

PMID 29486781PMC6389278DOI 10.1186/s13054-018-1967-3PUB-29486781

CC BY

Download PDF

PubMed tag: Review · 2019

Vasopressor therapy in critically ill patients with shock.

Russell et al. 2019Intensive care medicinecited by 147

PMID 31646370DOI 10.1007/s00134-019-05801-zPUB-31646370

Rights unknown

Source link

PubMed tag: none · 2016

Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis.

Stolk et al. 2016American journal of respiratory and critical care medicinecited by 114

PMID 27398737DOI 10.1164/rccm.201604-0862cpPUB-27398737

Full text at the publisher

Publisher page

PubMed tag: none · 2019

Corrected

Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial.

Laterre et al. 2019JAMAcited by 111

PMID 31577035PMC6802260DOI 10.1001/jama.2019.14607PUB-31577035

Rights unknown

Source link Read the notice

PubMed tag: review-article, Review · 2020

Vasopressin and its analogues in shock states: a review.

Demiselle et al. 2020Annals of intensive carecited by 85

PMID 31970567PMC6975768DOI 10.1186/s13613-020-0628-2PUB-31970567

CC BY

Download PDF

PubMed tag: none · 2021

Vasopressor Therapy in the Intensive Care Unit.

Russell et al. 2021Seminars in respiratory and critical care medicinecited by 57

PMID 32820475DOI 10.1055/s-0040-1710320PUB-32820475

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2019

Shock - Classification and Pathophysiological Principles of Therapeutics.

Kislitsina et al. 2019Current cardiology reviewscited by 47

PMID 30543176PMC6520577DOI 10.2174/1573403x15666181212125024PUB-30543176

Free to read · publisher termsCC BY-NC

Read at source

PubMed tag: Clinical Trial Protocol · 2018

Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial.

Lewis et al. 2018Annals of the American Thoracic Societycited by 29

PMID 29388815DOI 10.1513/annalsats.201708-669sdPUB-29388815

Full text at the publisher

Publisher page

PubMed tag: Review · 2016

Emerging drugs for the treatment of sepsis.

Heming et al. 2016Expert opinion on emerging drugscited by 23

PMID 26751198DOI 10.1517/14728214.2016.1132700PUB-26751198

Full text at the publisher

Publisher page

PubMed tag: none · 2010

Quantitative determination of peptide drug in human plasma samples at low pg/ml levels using coupled column liquid chromatography-tandem mass spectrometry.

Lövgren et al. 2010Journal of pharmaceutical and biomedical analysiscited by 18

PMID 20456896DOI 10.1016/j.jpba.2010.03.024PUB-20456896

Full text at the publisher

Publisher page

PubMed tag: Review · 2015

Emerging therapies for the treatment of sepsis.

Vincent et al. 2015Current opinion in anaesthesiologycited by 18

PMID 26087275DOI 10.1097/aco.0000000000000210PUB-26087275

Full text at the publisher

Publisher page

PubMed tag: review-article, Review · 2022

Alternatives to norepinephrine in septic shock: Which agents and when?

Jozwiak et al. 2022Journal of intensive medicinecited by 18

PMID 36788938PMC9924015DOI 10.1016/j.jointm.2022.05.001PUB-36788938

Free to read · publisher termsCC BY-NC-ND

Read at source

PubMed tag: Review · 2020

Vasopressors to treat refractory septic shock.

Meresse et al. 2020Minerva anestesiologicacited by 17

PMID 31994366DOI 10.23736/s0375-9393.20.13826-4PUB-31994366

Full text at the publisher

Publisher page

PubMed tag: none · 2020

Non-catecholamine vasopressors in the treatment of adult patients with septic shock-evidence from meta-analysis and trial sequential analysis of randomized clinical trials.

Zhong et al. 2020Journal of intensive carecited by 15

PMID 33292658PMC7603734DOI 10.1186/s40560-020-00500-0PUB-33292658

CC BY

Download PDF

PubMed tag: Meta-Analysis, Systematic Review · 2024

Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.

Kotani et al. 2024Critical care (London, England)cited by 15

PMID 39736782PMC11686893DOI 10.1186/s13054-024-05212-7PUB-39736782

Free to read · publisher termsCC BY-NC-ND

Read at source

PubMed tag: Review · 2017

The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock.

Saad et al. 2017Journal of critical carecited by 13

PMID 28319910DOI 10.1016/j.jcrc.2017.03.008PUB-28319910

Full text at the publisher

Publisher page

PubMed tag: Systematic Review · 2020

Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.

Rodriguez et al. 2020Journal of intensive care medicinecited by 13

PMID 30563433DOI 10.1177/0885066618818460PUB-30563433

Full text at the publisher

Publisher page

Newer studies

PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.

Selepressin studies: 11 papers with results

Page 1 of 1

Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.
Russell JA · Critical care (London, England) · 2017
Randomized controlled trial · 9 results
Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review.
Jozwiak M · Frontiers in medicine · 2022
Observational study · 1 result
A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock.
He X · Critical care medicine · 2016
Animal study (in vivo) · sheep · 19 results
Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs.
Boucheix OB · Shock (Augusta, Ga.) · 2013
Animal study (in vivo) · dog · 4 results
Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor.
Rehberg S · Critical care medicine · 2012
Animal study (in vivo) · sheep · 2 results
The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.
Maybauer MO · Critical care medicine · 2014
Animal study (in vivo) · sheep · 2 results
New, potent, selective, and short-acting peptidic V1a receptor agonists.
Wisniewski K · Journal of medicinal chemistry · 2011
Animal study (in vivo) · rat · 2 results
Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
Laporte R · The Journal of pharmacology and experimental therapeutics · 2011
Animal study (in vivo) · rat · 5 results
Selepressin, a novel selective V1A receptor agonist: Effect on mesenteric flow and gastric mucosa perfusion in the endotoxemic rabbit.
Milano SP · Peptides · 2020
Animal study (in vivo) · rabbit · 4 results
Selepressin and Arginine Vasopressin Do Not Display Cardiovascular Risk in Atherosclerotic Rabbit.
Boucheix O · PloS one · 2016
Animal study (in vivo) · rabbit · 8 results
Protective Mechanism of the Selective Vasopressin V1A Receptor Agonist Selepressin against Endothelial Barrier Dysfunction.
Barabutis N · The Journal of pharmacology and experimental therapeutics · 2020
In vitro (cells) · 9 results

Status and safety

Regulatory and safety

Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.

Regulatory status by jurisdiction, with date and source
Jurisdiction	Body	Status	As of	Source
US	FDA	No marketing approval was established. The FDA UNII record establishes substance identity only and explicitly does not imply approval. Drugs@FDA page extraction did not provide a usable product search result.	27 Oct 2026	precision.fda.gov (opens in a new tab)
EU	EMA	Central approval remains unverified. The EMA search page returned a timeout, then HTTP 403. Trial authorization does not establish marketing approval.	27 Oct 2026	ema.europa.eu (opens in a new tab)
Sport	WADA	Status unknown Selepressin is not named in the 2026 list.	2026 List	wada-ama.org (opens in a new tab)
National jurisdictions	Note	No national marketing authorization record was established. The FDA substance record is an identity record, not evidence of national approval.	27 Oct 2026	precision.fda.gov (opens in a new tab)

Safety outcomes

17 safety results for Selepressin.

Human evidence· 3

In septic shock, treatment-emergent adverse event frequency was similar with selepressin 2.5 ng/kg/minute and placebo.
Randomized controlled trialn = 40
In septic shock, one of two patients receiving selepressin 3.75 ng/kg/minute discontinued infusion for possible safety reasons, ending this dose group.
Randomized controlled trialn = 2
In worldwide pharmacovigilance reports, selepressin did not show a significant disproportionality association with acute mesenteric ischemia.
Observational studyn not reported

Animal evidence· 14

In sheep, the maximal vWF:Ag/Hb ratio with FE 202158 did not differ significantly from sham (9 ± 2%, p = .208).
Animal study (in vivo)sheepn = 6
Maximal vWF:Ag/Hb ratio
9%
FE 202158, percentage of baseline
In sheep, FE 202158 produced a lower maximal vWF:Ag/Hb ratio than arginine vasopressin (p < .005).
Animal study (in vivo)sheepn = 6
In endotoxemic rabbits, selepressin reduced mesenteric blood flow significantly less than arginine vasopressin.
Animal study (in vivo)rabbit
In rabbits with and without early-stage atherosclerosis, selepressin induced a slight dose-dependent increase in arterial pressure.
Animal study (in vivo)rabbit
In endotoxemic rabbits, selepressin reduced gastric mucosa perfusion significantly less than arginine vasopressin.
Animal study (in vivo)rabbit
In non-endotoxemic and endotoxemic rabbits, selepressin induced a pronounced dose-dependent increase in mesenteric vascular resistance.
Animal study (in vivo)rabbit
In rabbits, selepressin-induced mesenteric vascular resistance increases tended to be smaller with endotoxemia than without endotoxemia.
Animal study (in vivo)rabbit
In rabbits with and without early-stage atherosclerosis, selepressin moderately decreased heart rate.
Animal study (in vivo)rabbit

Doses studied · 6

The doses that these studies used. They are not recommendations.

2.5 ng/kg/minuteHuman
Species
human
Route
infusion
Duration
Until shock resolution or a maximum of 7 days
Design
Randomized controlled trial · n = 40
1.25 ng/kg/minuteHuman
Species
human
Route
infusion
Duration
Until shock resolution or a maximum of 7 days
Design
Randomized controlled trial · n = 31
3.75 ng/kg/minuteHuman
Species
human
Route
infusion
Duration
Until shock resolution or a maximum of 7 days
Design
Randomized controlled trial · n = 2
Initially 1 pmol/kg/min, then titratedAnimal
Species
sheep
Route
IV
Duration
Until death or maximum 30 hours
Design
Animal study (in vivo) · n = 46
1-300 ng · kg(-1) · min(-1)Animal
Species
dogs
Route
infusion
Duration
Not reported
Design
Animal study (in vivo) · n = 8
10 pmol·kg(-1)·min(-1)Animal
Species
sheep
Route
continuous intravenous infusion
Duration
120 minutes
Design
Animal study (in vivo) · n = 6

Doses studied in the study results, as given in the studies.
Dose as reported	Class	Species	Route	Duration	Design
2.5 ng/kg/minute	Human	human	infusion	Until shock resolution or a maximum of 7 days	Randomized controlled trial · n = 40
1.25 ng/kg/minute	Human	human	infusion	Until shock resolution or a maximum of 7 days	Randomized controlled trial · n = 31
3.75 ng/kg/minute	Human	human	infusion	Until shock resolution or a maximum of 7 days	Randomized controlled trial · n = 2
Initially 1 pmol/kg/min, then titrated	Animal	sheep	IV	Until death or maximum 30 hours	Animal study (in vivo) · n = 46
1-300 ng · kg(-1) · min(-1)	Animal	dogs	infusion	Not reported	Animal study (in vivo) · n = 8
10 pmol·kg(-1)·min(-1)	Animal	sheep	continuous intravenous infusion	120 minutes	Animal study (in vivo) · n = 6

PepBank is a research reference. Talk to a doctor before you use any peptide.

Data

Data and API

Data version, change history and code for this peptide.

Data version 30856030 Oct 2026

Peptide

Peptide id: PEP-000167
Peptide version: 2
Peptide hash: 165c7a9c2384a632…
Data version: 308560

Latest changes

27 Oct 2026UpdatedData version 287310
27 Oct 2026CreatedData version 256770

For developers

curl -s https://pepbank.io/v1/briefs/selepressin

Evidence summary for Selepressin: counts by class, key results with sources, notices, data version.

Peptide as JSON Evidence summary as JSON

Outcome group	Human	Animal	Lab	Computer model	Total
Blood pressureCardiovascular	Human: 5 results from 1 study: 2 increase, 2 decrease, 1 not reported. Strongest design: Randomized controlled trial	Animal: 9 results from 4 studies: 6 increase, 1 decrease, 1 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 increase. Strongest design: Ex vivo tissue	No results	15
Adverse eventsWhole body	Human: 3 results from 2 studies: 2 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	5
Electrolyte balanceWhole body	Human: 1 result from 1 study: 1 decrease. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 decrease. Strongest design: Animal study (in vivo)	No results	No results	3
Respiratory functionRespiratory	Human: 1 result from 1 study: 1 increase. Strongest design: Randomized controlled trial	No results	No results	No results	1
Vascular functionRespiratory	No results	Animal: 9 results from 4 studies: 3 increase, 5 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	Lab: 5 results from 1 study: 1 increase, 4 decrease. Strongest design: In vitro (cells)	No results	14
Heart functionCardiovascular	No results	Animal: 8 results from 3 studies: 2 increase, 3 decrease, 3 no significant change. Strongest design: Animal study (in vivo)	No results	No results	8
Receptor activity and mechanismRespiratory	No results	Animal: 2 results from 2 studies: 1 increase, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 5 results from 3 studies: 3 increase, 1 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	7
Inflammation markersImmune and inflammation	No results	Animal: 4 results from 1 study: 4 decrease. Strongest design: Animal study (in vivo)	No results	No results	4
Lung injury and fibrosisRespiratory	No results	Animal: 4 results from 1 study: 4 decrease. Strongest design: Animal study (in vivo)	No results	No results	4
Kidney functionKidney and urinary	No results	Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	1
MortalityWhole body	No results	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	1

Outcome group	Human	Animal	Lab	Computer model	Total
Blood pressureCardiovascular	Human: 5 results from 1 study: 2 increase, 2 decrease, 1 not reported. Strongest design: Randomized controlled trial	Animal: 9 results from 4 studies: 6 increase, 1 decrease, 1 no significant change, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 1 result from 1 study: 1 increase. Strongest design: Ex vivo tissue	No results	15
Adverse eventsWhole body	Human: 3 results from 2 studies: 2 no significant change, 1 not reported. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 1 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	No results	No results	5
Electrolyte balanceWhole body	Human: 1 result from 1 study: 1 decrease. Strongest design: Randomized controlled trial	Animal: 2 results from 1 study: 2 decrease. Strongest design: Animal study (in vivo)	No results	No results	3
Respiratory functionRespiratory	Human: 1 result from 1 study: 1 increase. Strongest design: Randomized controlled trial	No results	No results	No results	1
Vascular functionRespiratory	No results	Animal: 9 results from 4 studies: 3 increase, 5 decrease, 1 no significant change. Strongest design: Animal study (in vivo)	Lab: 5 results from 1 study: 1 increase, 4 decrease. Strongest design: In vitro (cells)	No results	14
Heart functionCardiovascular	No results	Animal: 8 results from 3 studies: 2 increase, 3 decrease, 3 no significant change. Strongest design: Animal study (in vivo)	No results	No results	8
Receptor activity and mechanismRespiratory	No results	Animal: 2 results from 2 studies: 1 increase, 1 not reported. Strongest design: Animal study (in vivo)	Lab: 5 results from 3 studies: 3 increase, 1 decrease, 1 not reported. Strongest design: In vitro (cells)	No results	7
Inflammation markersImmune and inflammation	No results	Animal: 4 results from 1 study: 4 decrease. Strongest design: Animal study (in vivo)	No results	No results	4
Lung injury and fibrosisRespiratory	No results	Animal: 4 results from 1 study: 4 decrease. Strongest design: Animal study (in vivo)	No results	No results	4
Kidney functionKidney and urinary	No results	Animal: 1 result from 1 study: 1 not reported. Strongest design: Animal study (in vivo)	No results	No results	1
MortalityWhole body	No results	Animal: 1 result from 1 study: 1 increase. Strongest design: Animal study (in vivo)	No results	No results	1

Selepressin studies and research data

Selepressin identity

Targets

Sequence and structure

Sequence

Parent: Arginine vasopressin (human)

Properties

Net charge by pH

Composition

3D structure

2D structure

Selepressin results by year and outcome

What the studies measured

Selepressin studies on heart and blood vessels

Selepressin studies on side effects

Selepressin studies on lungs and breathing

Selepressin studies on salt, water and minerals

Selepressin studies on immune system and inflammation

Selepressin studies on receptors and cell signals

Selepressin studies on kidneys and bladder

Selepressin studies on survival and serious illness

Selepressin trials

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

Papers

Studies with results

Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.

A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock.

The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis*.

New, potent, selective, and short-acting peptidic V1a receptor agonists.

Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.

Vasopressors and Risk of Acute Mesenteric Ischemia: A Worldwide Pharmacovigilance Analysis and Comprehensive Literature Review.

Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor.

Selepressin, a new V1A receptor agonist: hemodynamic comparison to vasopressin in dogs.

More studies

Vasoplegia treatments: the past, the present, and the future.

Vasopressor therapy in critically ill patients with shock.

Potentially Inadvertent Immunomodulation: Norepinephrine Use in Sepsis.

Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: The SEPSIS-ACT Randomized Clinical Trial.

Vasopressin and its analogues in shock states: a review.

Vasopressor Therapy in the Intensive Care Unit.

Shock - Classification and Pathophysiological Principles of Therapeutics.

Rationale and Design of an Adaptive Phase 2b/3 Clinical Trial of Selepressin for Adults in Septic Shock. Selepressin Evaluation Programme for Sepsis-induced Shock-Adaptive Clinical Trial.

Emerging drugs for the treatment of sepsis.

Quantitative determination of peptide drug in human plasma samples at low pg/ml levels using coupled column liquid chromatography-tandem mass spectrometry.

Emerging therapies for the treatment of sepsis.

Alternatives to norepinephrine in septic shock: Which agents and when?

Vasopressors to treat refractory septic shock.

Non-catecholamine vasopressors in the treatment of adult patients with septic shock-evidence from meta-analysis and trial sequential analysis of randomized clinical trials.

Non-adrenergic vasopressors for vasodilatory shock or perioperative vasoplegia: a meta-analysis of randomized controlled trials.

The role of vasopressin and the vasopressin type V1a receptor agonist selepressin in septic shock.

Novel Vasopressors in the Treatment of Vasodilatory Shock: A Systematic Review of Angiotensin II, Selepressin, and Terlipressin.

Newer studies

Selepressin studies: 11 papers with results

Regulatory and safety

Human evidence· 3

Animal evidence· 14

Doses studied · 6

Data and API

Peptide

Latest changes

For developers

Related peptides

Selepressin results by year and outcome

Selepressin studies on heart and blood vessels

Selepressin studies on side effects

Selepressin studies on lungs and breathing

Selepressin studies on salt, water and minerals

Selepressin studies on immune system and inflammation

Selepressin studies on receptors and cell signals

Selepressin studies on kidneys and bladder

Selepressin studies on survival and serious illness

Selepressin trials

Selepressin Evaluation Programme for Sepsis-Induced Shock - Adaptive Clinical Trial

Effects of the V1a Agonist FE 202158 in Patients With Septic Shock

Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock

Papers

Studies with results

Selepressin, a novel selective vasopressin V1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.

Selepressin, a novel selective vasopressin V_1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.

Selepressin, a novel selective vasopressin V_1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients.